Let My Doctors Decide Action Network

What keeps pharmacy stakeholders up at night? A recent survey highlights key concerns around #PBMs and high out-of-pocket costs.

In this interview, Dr. Mattie Feldman shares her perspective on the Federal Trade Commission interim report and ongoing scrutiny of #PBMs. More from Coalition of State Rheumatology Organizations (CSRO)'s own here:

Important read in Colorado Politics: Colorado's #PDAB doesn’t address the key factor in driving up prices for prescription medicines. #PBMs have been increasing costs and pocket the profits for decades with little attention or oversight.

National Eczema Association needs support to be eligible for #DepartmentofDefense Peer-Reviewed Medical Research funding. Let's help them push it across the finish line. Learn more here:

Read this reporting in Healthcare Dive: The House Committee on Oversight and Accountability Chair is threatening the leaders of the three largest #PBMs with steep fines or jail time for allegedly lying in a recent congressional hearing. https://lnkd.in/gvC_eHqd

You are not alone: Millions of patients across the country face barriers to accessing the treatments their doctors prescribe. If you have struggled with obstacles at the hands of third-party inference, we want to hear from you. https://lnkd.in/ei7Erwbc

A recent poll found that more than 80% of likely voters support #PBMreforms to require prescription drug discounts be passed along to consumers instead of being pocketed by #PBM middlemen. Congress must act now. https://lnkd.in/g36gWy48

This op-ed from Nevada Attorney General Aaron Ford explains why pharmacy benefit managers (#PBMs) are under a microscope in the state. Learn more about the need for increased accountability here:

To conclude #ChronicDiseaseMonth, the Chronic Disease Coalition called on policymakers to help chronic disease patients by evaluating the impact of health care access and affordability policies, include patient voices, and connect with the community. Read more:

Pharmacy benefit managers (#PBMs) shouldn’t have free rein to drive up drug prices, the Boston Globe Media editorial board says. “PBMs have potential to drive drug prices down and save consumers money. They shouldn’t be allowed to do the exact opposite.”